Breaking the Vicious Cycle: How TRPV1 Channels Drive Corneal Nerve Damage in Dry Eye Disease

Thank you for my dear Patient who brought in an article recently published on the below exciting new breakthrough and Dry Eye disease treatments. It’s not ready yet for purchase, but it is on its way.

For the millions of people worldwide suffering from dry eye disease and related conditions, the below research offers genuine hope. It suggests that more targeted, effective treatments are on the horizon—treatments that address not just the surface symptoms but the underlying neurosensory dysfunction.  

  

If you've ever experienced dry, irritated eyes, you know how uncomfortable it can be. But for millions of people, dry eye isn't just an annoyance—it's a source of chronic, debilitating pain. And until recently, we didn't fully understand why.  

  

Today, we're exploring groundbreaking research published in Experimental  Molecular Medicine that reveals a previously unknown neuroinflammatory circuit connecting the cornea to the brain. This discovery could revolutionize how we treat not just dry eye, but a range of ocular surface diseases.  

The cornea—that clear, dome-shaped surface covering the front of your eye—is actually the most densely innervated tissue in your entire body. It has more nerve endings per square millimeter than anywhere else, which makes sense when you think about it. Your cornea needs to detect the tiniest particle of dust, the slightest change in moisture, even subtle shifts in temperature.  

  

These nerve fibers don't just sit in the cornea, though. They're connected to a structure called the trigeminal ganglion, which is located in your skull. Think of the trigeminal ganglion as a relay station—it's where the cell bodies of these sensory neurons live, and it's where signals from your cornea get processed before being sent to your brain.  

  

Now, here's where things get interesting. Researchers have discovered that when dry eye develops, it triggers a vicious cycle involving both the cornea and this trigeminal ganglion. And at the center of this cycle is something called TRPV1.  

  

TRPV1 stands for "transient receptor potential vanilloid 1". But you might know it better as the capsaicin receptor. Yes, the same receptor that makes hot peppers feel hot. TRPV1 channels are found on nerve fibers throughout your body, including in your cornea, and they act as sensors for pain, heat, and inflammation.  

  

In healthy eyes, TRPV1 channels help your cornea detect potential threats. But in dry eye disease, something goes wrong. The tear deficiency and tissue damage cause these TRPV1 channels to become overactive. And that's where our story really begins.  

The research team, led by Dr. Jeremías Galleti and colleagues, used a mouse model of dry eye to map out exactly what happens when TRPV1 channels become overactivated. What they found was remarkable.  

  

When TRPV1 channels in the cornea are triggered by tear deficiency and damage, they don't just send pain signals to the brain. They actually initiate a complex inflammatory response that involves both the cornea and the trigeminal ganglion.  

  

Here's how the cycle works:  

  

First, TRPV1 activation in the cornea triggers the release of inflammatory molecules and activates immune cells called macrophages on the ocular surface. But the signal doesn't stop there. It travels along the nerve fibers to the trigeminal ganglion, where it causes neuroinflammatory gene expression and activates macrophages in the ganglion itself.  

  

Now, you might think, "Okay, so there's inflammation in both places. What's the big deal?" Well, here's where it gets really interesting. This inflammation in the trigeminal ganglion actually feeds back to affect the cornea. It leads to progressive nerve degeneration—the corneal nerves literally start to break down. The cornea loses sensitivity to touch and certain chemical stimuli. And paradoxically, while the cornea becomes less sensitive to some stimuli, the TRPV1 channels themselves become even more sensitive.  

 This creates what the researchers call a "vicious neurosensory cycle." The more TRPV1 channels are activated, the more inflammation occurs in the trigeminal ganglion. The more inflammation in the ganglion, the more nerve damage in the cornea. And the more nerve damage, the more dysregulated the TRPV1 channels become. Round and round it goes.  

  Now, one of the most compelling aspects of this research is what happened when the team activated TRPV1 channels without causing dry eye. They wanted to know: is TRPV1 activation alone sufficient to trigger this whole cascade, or does it require the ongoing tissue damage from dry eye?  

  

The answer was clear: TRPV1 activation alone was enough. Even without ocular desiccation, activating these channels triggered macrophage reactivity, corneal nerve degeneration, and trigeminal neuroinflammation. This tells us that TRPV1 isn't just responding to dry eye—it's actively driving the neurosensory dysfunction.  

  

But here's where the story gets even more interesting. The researchers identified a key player in this circuit: a molecule called substance P.  

  

Substance P is what we call a neuropeptide—a small protein that nerves use to communicate. When TRPV1 channels are activated, they trigger the release of substance P from nerve endings. And substance P is a powerful inflammatory mediator. It activates immune cells, promotes the release of other inflammatory molecules, and helps propagate the inflammatory signal from the cornea to the trigeminal ganglion and back.  

  

The researchers tested what would happen if they blocked substance P. And the results were striking: blocking substance P reversed most of the TRPV1-driven corneal neurosensory abnormalities. The nerve degeneration was reduced, the inflammation in the trigeminal ganglion decreased, and the corneal sensitivity improved.  

  

So what does all this mean for patients and clinicians? Well, this research fundamentally changes how we think about dry eye disease and corneal neuropathy.  

  

Traditionally, we've thought of nerve damage in dry eye as a consequence of surface inflammation—the idea being that if we can reduce inflammation on the ocular surface, the nerves will recover. But this research shows that nerve damage is actually part of an active neuroinflammatory circuit that involves the central nervous system. It's not just a passive consequence; it's an active, self-perpetuating process.  

This explains several puzzling clinical observations. For instance, why does dry eye pain often persist even after surface inflammation improves? Because the neuroinflammatory circuit in the trigeminal ganglion continues to drive dysfunction. Why do some patients develop such severe pain sensitivity? Because the TRPV1 channels become progressively more sensitized as the cycle continues.  

The therapeutic implications are exciting. This research suggests several potential treatment targets.  

First, TRPV1 antagonists—drugs that block these channels—could interrupt the vicious cycle at its source. Previous research has already shown that TRPV1 antagonists can reduce corneal pain and neuroinflammation in severe dry eye. One study using a drug called capsazepine demonstrated significant improvements in pain behavior and reduced neuroinflammatory markers in the trigeminal ganglion.  

Second, targeting substance P or its receptor could prevent the propagation of inflammation between the cornea and trigeminal ganglion. Recent studies have shown that blocking the substance P receptor, called NK-1R, can reduce pain perception and even support nerve regeneration following corneal injury.  

Third, and perhaps most importantly, this research suggests that combination therapies targeting multiple points in the pathway might be most effective. Rather than just treating surface inflammation, we might need to address the neuroinflammatory component as well.  

It's worth noting that this corneal-trigeminal axis isn't unique to dry eye disease. Other research has shown that various types of ocular surface injury—chemical burns, infections, even some surgical procedures—can trigger similar neuroinflammatory responses in the trigeminal ganglion.  

  

One particularly interesting study used MRI imaging to actually visualize inflammation in the trigeminal ganglion following corneal injury. They found that macrophages infiltrated the ganglion and that inflammatory cytokines were significantly elevated. And critically, treating the corneal inflammation with anti-inflammatory drugs reduced the inflammation in the trigeminal ganglion as well.  

This bidirectional communication between the cornea and the brain highlights just how interconnected our nervous and immune systems are. It's not enough to think of the eye in isolation—we need to consider the entire neural circuit.  

Another fascinating aspect of this research relates to substance P itself. Substance P has what scientists call a "two-faced" role in corneal health. On one hand, it's essential for normal corneal function. It promotes wound healing, helps maintain the corneal epithelium, and regulates tear secretion. Patients with reduced substance P levels, such as those with diabetic neuropathy, often have impaired corneal healing.  

But on the other hand, excessive substance P contributes to pain, inflammation, and even abnormal blood vessel growth in the cornea. Following ocular surface inflammation, trigeminal neurons that normally don't produce substance P can start expressing it—a phenomenon called phenotypic switching. And this change can persist long after the initial inflammation resolves, potentially contributing to chronic pain.  

So the challenge for future therapies will be finding the right balance—blocking the excessive, pathological effects of substance P while preserving its beneficial roles in corneal homeostasis.  

The future of dry eye treatment:

Currently, most dry eye therapies focus on the ocular surface: artificial tears to supplement moisture, anti-inflammatory drops to reduce surface inflammation, or procedures to improve tear retention.  

These treatments can be effective, but they don't address the underlying neuroinflammatory circuit. This research suggests that we might need to add neuroprotective strategies to our treatment arsenal—therapies specifically designed to protect corneal nerves and interrupt the neuroinflammatory cycle.    

Some of these approaches are already in development. TRPV1 antagonists are being investigated for various pain conditions, and some have shown promise in ocular applications. NK-1R antagonists, which block substance P signaling, are already FDA-approved for other indications like chemotherapy-induced nausea, and researchers are exploring their potential for ocular pain.  

There's also growing interest in combination therapies that address both surface inflammation and neuroinflammation simultaneously. For instance, combining traditional anti-inflammatory treatments with neuroprotective agents might be more effective than either approach alone.  

It's important to note that while this research was conducted in mice, the findings have strong translational potential. The basic anatomy and physiology of corneal innervation are remarkably similar between mice and humans. And clinical studies have already confirmed that TRPV1 channels are sensitized in human patients with dry eye disease, and that substance P levels are altered in various ocular surface conditions.  

  

I want to emphasize just how significant this discovery is. For decades, we've known that corneal nerves are important in dry eye disease, but we've lacked a clear mechanistic understanding of how nerve damage occurs and perpetuates.  

  

This research provides that mechanism. It shows us that corneal neuropathy isn't just collateral damage from surface inflammation—it's an active process driven by a specific neuroinflammatory circuit involving TRPV1 channels, substance P, and bidirectional communication between the cornea and trigeminal ganglion.  

  

Understanding this circuit opens up entirely new avenues for treatment. Instead of just managing symptoms, we might be able to actually interrupt the pathological process driving corneal nerve dysfunction.   

The cornea may be small, but its neural circuitry is remarkably complex. We're only beginning to understand the intricate connections between the eye and the brain, and how these connections can go awry in disease. But with each discovery, we get closer to developing therapies that can truly restore ocular health and comfort.   

References

1. A Transient Receptor Potential Vanilloid 1-Dependent Corneal-Trigeminal Neuroinflammatory Circuit Promotes Corneal Neuropathy. Pizzano M, Vereertbrugghen A, Martinez Gomez MJ, et al. Experimental & Molecular Medicine. 2026;:10.1038/s12276-026-01653-y. doi:10.1038/s12276-026-01653-y.

2. Transient Receptor Potential Vanilloid-1 Channels Facilitate Axonal Degeneration of Corneal Sensory Nerves in Dry Eye. Pizzano M, Vereertbrugghen A, Cernutto A, et al. The American Journal of Pathology. 2024;194(5):810-827. doi:10.1016/j.ajpath.2024.01.015.

3. Chronic Tear Deficiency Sensitizes Transient Receptor Potential Vanilloid 1-Mediated Responses in Corneal Sensory Nerves. Masuoka T, Yamashita Y, Nakano K, et al. Frontiers in Cellular Neuroscience. 2020;14:598678. doi:10.3389/fncel.2020.598678.

4. Ocular Surface Injury Induces Inflammation in the Brain: In Vivo and Ex Vivo Evidence of a Corneal-Trigeminal Axis. Ferrari G, Bignami F, Giacomini C, et al. Investigative Ophthalmology & Visual Science. 2014;55(10):6289-300. doi:10.1167/iovs.14-13984.

5. The Two-Faced Effects of Nerves and Neuropeptides in Corneal Diseases. Lasagni Vitar RM, Rama P, Ferrari G. Progress in Retinal and Eye Research. 2022;86:100974. doi:10.1016/j.preteyeres.2021.100974.

6. Antagonizing NK-1R Modulates Pain Perception Following Corneal Injury. Surico PL, Naderi A, Singh RB, et al. Experimental Eye Research. 2025;251:110230. doi:10.1016/j.exer.2025.110230.

7. Capsazepine Decreases Corneal Pain Syndrome in Severe Dry Eye Disease. Fakih D, Guerrero-Moreno A, Baudouin C, Réaux-Le Goazigo A, Parsadaniantz SM. Journal of Neuroinflammation. 2021;18(1):111. doi:10.1186/s12974-021-02162-7.

8. Morphological and Functional Changes of Corneal Nerves and Their Contribution to Peripheral and Central Sensory Abnormalities. Guerrero-Moreno A, Baudouin C, Melik Parsadaniantz S, Réaux-Le Goazigo A. Frontiers in Cellular Neuroscience. 2020;14:610342. doi:10.3389/fncel.2020.610342.

9. Ocular Inflammation Induces Trigeminal Pain, Peripheral and Central Neuroinflammatory Mechanisms. Launay PS, Reboussin E, Liang H, et al. Neurobiology of Disease. 2016;88:16-28. doi:10.1016/j.nbd.2015.12.017.

10. Ocular Surface Inflammation Induces De Novo Expression of Substance P in the Trigeminal Primary Afferents With Large Cell Bodies. Byun YS, Mok JW, Chung SH, Kim HS, Joo CK. Scientific Reports. 2020;10(1):15210. doi:10.1038/s41598-020-72295-x.